DMSO：33.33 mg / mL（109.17 mM;需要超聲波）

[1]. Piccini P, Brooks DJ, Korpela K, The catechol-O-methyltransferase(COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 May;68(5):589-94.

[2]. Di Giovanni S, Eleuteri S, Paleologou KE, Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem. 2010 May 14;285(20):1494

[3]. Sethi KD, Hauser RA, Isaacson SH, Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series. Cases J. 2009 Jul 30;2:7134.

[4]. Poulopoulos M, Waters C. Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease. Core Evid. 2010 Jul 27;5:1-10.

1、 摩爾折射率：79.12

2、 摩爾體積（cm3/mol）：219.2

3、 等張比容（90.2K）：629.8

4、 表面張力（dyne/cm）：68.1

5、 極化率（10-24cm3）：31.36

1.疏水參數(shù)計算參考值（XlogP）:2.1

2.氫鍵供體數(shù)量:2

3.氫鍵受體數(shù)量:6